Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has announced a multi-year expansion of its U.S. manufacturing operations at its headquarters in Rancho Cucamonga, California, with plans to quadruple production capacity over the next three to five years. The bio-pharmaceutical company, which focuses on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, describes this as the most substantial investment in domestic infrastructure in the company's history.
Strategic Infrastructure Investment
The expansion will feature a new state-of-the-art production plant, expanded automation, and the integration of advanced technologies to support the development and manufacture of critical medications. The initiative is specifically designed to support the production of new pipeline candidates while strengthening supply chain resilience for existing products.
"Expanding our domestic manufacturing footprint is not only a strategic milestone for Amphastar but a reaffirmation of our commitment to producing essential medicines right here in the United States," said Dr. Jack Zhang, Amphastar's President and CEO. "All of our finished pharmaceutical products are proudly manufactured in the U.S., and this long-term investment strengthens the commitment, enhancing our ability to deliver greater flexibility, agility, and quality to the healthcare providers and patients who depend on our products every day."
Job Creation and Workforce Development
Once completed, the company expects to create new jobs across multiple departments including research and development, engineering, manufacturing, and quality operations. Amphastar plans to work in close partnership with all levels of government leadership to ensure sustainable growth, workforce development, and alignment with economic and public health priorities.
Company Profile and Market Focus
Amphastar specializes in technically-challenging generic and proprietary injectable, inhalation, and intranasal products, with additional insulin API product sales. Most of the company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
The company's product portfolio includes branded medications such as BAQSIMI®, Primatene MIST®, REXTOVY™, Amphadase®, and Cortrosyn®. The expansion reinforces Amphastar's commitment to domestic pharmaceutical manufacturing at a time when supply chain resilience has become increasingly important for critical medications.
